Early and locally advanced breast cancer: Diagnosis and treatment
This is an extract from the guidance and may be misleading if read alone. The complete guidance is available at guidance.nice.org.uk/cg80
Important information about this guideline
This guideline updates the following technology appraisals:
-
'Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer' (NICE technology appraisal guidance 107)
-
'Paclitaxel for the adjuvant treatment of early node-positive breast cancer' (NICE technology appraisal guidance 108)
-
'Docetaxel for the adjuvant treatment of early node-positive breast cancer' (NICE technology appraisal guidance 109)
NICE and the Department of Health are currently reviewing the future position on updating technology appraisals within clinical guidelines, with particular reference to implications for the funding direction on technology appraisals. In the meantime, the technology appraisal guidance remains available and should continue to be followed. The statutory funding direction remains in place for the recommendations contained in the technology appraisal guidance.